Arovella Therapeutics Limited (ASX: ALA)
Health Care · Pharmaceuticals · AU
AU$0.05
+10.64% today · -45.3% 1Y
Arovella Therapeutics Limited (ASX: ALA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $43.87M and employs 27 people.
Over the last twelve months the share price has lost 45.3%, trading between 0.05 and 0.10.
Tweenvest scores Arovella Therapeutics Limited across four factors: quality 37/100, value 58/100. Its strongest factor is value.
ALA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $43.87M
- Revenue (TTM)
- $2.42M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.17
- 52-week high
- AU$0.10
- 52-week low
- AU$0.05
- Avg volume (3M)
- —
- Shares outstanding
- 1.21B
- Employees
- 27
- Next earnings
- —
About Arovella Therapeutics Limited
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
- ISIN
- AU0000182784
- Founded
- 1999
- Listed since
- Jan 22, 2002
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Vext Science, Inc.CNSX: VEXT | $45.14M | CA$0.26 | +15.56% |
| Yuyu Pharma, Inc.KOSE: A000220 | $44.98M | ₩3,840.00 | +1.59% |
| Oncoinvent ASAOB: ONCIN | $44.84M | Nkr69.40 | -0.86% |
| Advagene Biopharma Co., Ltd.TPEX: 6709 | $44.48M | NT$23.95 | -0.21% |
| Grace Therapeutics, Inc.NasdaqCM: GRCE | $43.75M | $1.98 | -4.81% |
| Entropy Neurodynamics LimitedASX: EX1 | $43.32M | AU$— | — |
| Entropy Neurodynamics LimitedASX: ENP | $43.32M | AU$0.04 | -2.56% |
| Avecho Biotechnology LimitedASX: AVE | $43.14M | AU$0.02 | -20.00% |
Figures last refreshed Oct 11, 2026.